High-risk prostate cancer: A disease of genomic instability

被引:26
|
作者
Tapia-Laliena, Maria A. [1 ]
Korzeniewski, Nina [1 ]
Hohenfellner, Markus [1 ]
Duensing, Stefan [1 ]
机构
[1] Heidelberg Univ, Sch Med, Dept Urol, Heidelberg, Germany
关键词
Prostate cancer; Genomic instability; Somatic mutations; DNA damage; Translational therapeutics; Biomarkers; IN-SITU HYBRIDIZATION; DNA-REPAIR; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; ERG; FUSION; REARRANGEMENT; MUTATIONS; DELETIONS; CHROMOTHRIPSIS;
D O I
10.1016/j.urolonc.2014.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: In this review, we will discuss the latest advances in our understanding of the relationship between the cellular DNA damage response and genomic instability in prostate cancer and the emerging possibilities to exploit these aberrations as prognostic biomarkers and guides for personalized patient management. Methods: Important findings related to genomic instability in prostate cancer were retrieved from the literature and combined with our own results and a translational perspective. Results: Prostate cancer is characterized by a highly altered genomic landscape with a wide spectrum of genomic alterations, including somatic mutations, copy number alterations (CNAs), gene fusions, complex chromosomal rearrangements, and aneuploidy. In addition, massive DNA damaging events, including chromothripsis and chromoplexy, which can lead to extensive genomic insults in a single step, have been identified. A number of these genomic aberrations have been found to provide prognostic information and can therefore help to identify high-risk patients. In addition, defects in the DNA damage checkpoint and repair machinery can potentially be harnessed for therapeutic purposes. Conclusions: Genomic instability plays a crucial role in the malignant progression of prostate cancer and can be exploited for the development of novel prognostic biomarkers and innovative therapies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 50 条
  • [1] Identifying high risk features and genomic instability in men with familial prostate cancer
    Risbridger, G.
    Sliwinski, A.
    Thorne, H.
    Taylor, R.
    Papargiris, M.
    Hunter, S.
    Campbell, I.
    Thorne, H.
    Li, J.
    Mitchell, G.
    Clouston, D.
    Bristow, R.
    Murphy, D.
    Frydenberg, M.
    Bolton, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S500 - S501
  • [2] Genomic Instability and Prostate Cancer Risk in New Zealand
    Ferguson, L. R.
    Karunasinghe, N.
    Vaidayanathan, V.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2018, 59 : 81 - 81
  • [4] High-risk prostate cancer: treat the prostate
    Cooperberg, Matthew R.
    LANCET, 2011, 378 (9809): : 2056 - 2057
  • [5] Genomic instability in prostate cancer
    Lee, Edmund C.
    Li, Reli
    Ayala, Gustavo
    Cai, Wei-Wen
    Greenberg, Norman
    CANCER RESEARCH, 2006, 66 (08)
  • [6] High Genomic Instability Predicts Survival in Metastatic High-Risk Neuroblastoma
    Stigliani, Sara
    Coco, Simona
    Moretti, Stefano
    Oberthuer, Andre
    Fischer, Mattias
    Theissen, Jessica
    Gallo, Fabio
    Garaventa, Alberto
    Berthold, Frank
    Bonassi, Stefano
    Tonini, Gian Paolo
    Scaruffi, Paola
    NEOPLASIA, 2012, 14 (09): : 823 - U181
  • [7] The high-risk prostate cancer patient
    Hussain, M
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (03) : 211 - 211
  • [8] Radiotherapy for high-risk prostate cancer
    Jahan J. Mohiuddin
    Brock R. Baker
    Ronald C. Chen
    Nature Reviews Urology, 2015, 12 : 145 - 154
  • [9] Defining high-risk prostate cancer
    Goldberg, Hanan
    Baniel, Jack
    Yossepowitch, Ofer
    CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 337 - 341
  • [10] The epidemiology of high-risk prostate cancer
    Punnen, Sanoj
    Cooperberg, Matthew R.
    CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 331 - 336